(ANSA) – ROME, FEBRUARY 21 – This week Germany will offer its population a new protein-based vaccine against Covid-19; mRNA used in the most commonly used vaccines. The Guardian writes it.
About 1.4 million doses of the Nuvaxovid vaccine, developed by US biotechnology company Novavax, will arrive in Germany this week, the country’s health minister Karl Lauterbach confirmed. Another million doses will arrive the following week. The total German government order for the year 2022 is 34 million doses.
The Guardian recalls that Novavax has so far been used in Indonesia and the Philippines, although it was allowed for use in the European Union last December. It is still pending clearance in the United States as concerns about the company’s production capacity persist. (HANDLE).
Source: Ansa
I have been working in the news industry for over 10 years now and I have worked for some of the biggest news websites in the world. My focus has always been on entertainment news, but I also cover a range of other topics. I am currently an author at Global happenings and I love writing about all things pop-culture related.
